Last Traded Price 230.00 + 0.00 %
| Periods | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 3 Years | All Time |
|---|---|---|---|---|---|---|---|
| Primex-40 | |||||||
| Aditya Birla Capital Limited |
|
Particulars |
31-03-2024 |
31-03-2023 |
|
Financial Assets |
|
|
|
Cash and Cash Equivalents |
1,554.30 |
1,730.79 |
|
Bank Balances other than above |
2,024.71 |
585.07 |
|
Derivative Financial Instruments |
360.15 |
5.97 |
|
Trade Receivables |
698.14 |
411.08 |
|
Other Receivables |
16.08 |
0.00 |
|
Loans |
1,23,117.76 |
93,427.26 |
|
Investments of Life Insurance Policyholders |
46,652.12 |
36,943.85 |
|
Investments of Life Insurance Shareholders |
4,000.98 |
3,302.91 |
|
Other Investments |
8,486.97 |
5,326.49 |
|
Assets Held to Cover Linked Liabilities |
36,005.19 |
30,505.79 |
|
Other Financial Assets |
1,817.69 |
1,785.42 |
|
Non-Financial Assets |
|
|
|
Current Tax Assets (Net) |
119.63 |
231.73 |
|
Deferred Tax Assets (Net) |
517.91 |
476.73 |
|
Investment Property |
13.94 |
14.37 |
|
Property, Plant and Equipment |
255.44 |
147.62 |
|
Capital Work-in-Progress |
9.65 |
8.62 |
|
Intangible Assets Under Development |
84.58 |
35.42 |
|
Goodwill |
554.83 |
554.83 |
|
Other Intangible Assets |
262.62 |
168.34 |
|
Right-to-Use of Assets |
565.50 |
393.58 |
|
Investments in Associates and Joint Ventures |
4,393.65 |
4,303.82 |
|
Other Non-Financial Assets |
585.55 |
394.36 |
|
Assets Held for Sale |
4.44 |
0.00 |
|
Total Assets |
2,32,101.83 |
1,80,754.05 |
|
Financial Liabilities |
|
|
|
Derivative Financial Instruments |
97.49 |
13.69 |
|
Pyabales: |
|
|
|
Total Outstanding dues of Micro & Small Enterprises |
30.89 |
24.97 |
|
Total Outstanding dues of Creditors Other than above |
1,382.19 |
1,381.60 |
|
Debt Securities |
36,895.55 |
27,244.86 |
|
Borrowings (other than Debt Securities) |
68,834.42 |
53,815.47 |
|
Subordinated Liabilities |
3,810.13 |
3,260.44 |
|
Lease Liabilities |
599.24 |
416.73 |
|
Policyholders ' Liabilities |
85,388.46 |
69,089.94 |
|
Other Financial Liabilities |
5,026.42 |
2,562.74 |
|
Non-Financial Liabilities |
|
|
|
Current Tax Liabilities (Net) |
315.56 |
185.78 |
|
Provisions |
319.02 |
264.04 |
|
Deferred Tax Liabilities (Net) |
478.54 |
401.54 |
|
Other Non-Financial Liabilities |
286.14 |
272.18 |
|
Equity |
|
|
|
Equity Share Capital |
2,600.02 |
2,417.99 |
|
Other Equity |
24,217.24 |
17,892.76 |
|
Equity Attributable to Owners |
26,817.26 |
20,310.75 |
|
Non-Controlling Interests |
1,820.52 |
1,509.32 |
|
Total Liabilities and Equity |
2,32,101.83 |
1,80,754.05 |
|
Particulars |
31-03-2024 |
31-03-2023 |
|
Revenue from Operations |
|
|
|
Interest Income |
14,290.58 |
9,563.16 |
|
Dividend Income |
2.72 |
2.92 |
|
Fees and Commission Income |
1,348.54 |
1,240.67 |
|
Net Gain on Fair Value Changes |
362.13 |
114.35 |
|
Net Gain on De-recognition of Financial Assets |
58.98 |
- |
|
Gain on Sale of Investments |
486.43 |
- |
|
Life Insurance Policyholders ' Income |
17,950.07 |
15,186.08 |
|
Health Insurance Policyholders ' Income |
- |
1,300.58 |
|
Sale of Services |
6.09 |
7.89 |
|
Other Income |
55.04 |
2,785.68 |
|
Total Income |
34,560.58 |
30,201.33 |
|
Expenses |
|
|
|
Finance Costs |
7,617.25 |
4,722.00 |
|
Fees and Commission Expense |
478.19 |
470.25 |
|
Impairment on Financial Instruments |
1,352.29 |
981.09 |
|
Employee Benefits Expenses |
1,537.88 |
1,140.07 |
|
Life Insurance Policyholders ' Expenses |
17,869.93 |
15,125.69 |
|
Health Insurance Policyholders ' Expenses |
- |
1,472.03 |
|
Depreciation and Amortisation |
193.82 |
144.83 |
|
Other Expenses |
1,232.77 |
782.71 |
|
Total Expenses |
30,282.13 |
24,838.67 |
|
Profit Before Share of Associates and Joint Ventures and Tax |
4,278.45 |
5,362.66 |
|
Share of Profit/(Loss) of Associate and Joint Venture Companies |
303.91 |
272.57 |
|
Profit Before Tax |
4,582.36 |
5,635.23 |
|
Current Tax relating to other than revenue account |
1,072.85 |
856.81 |
|
Short/(Excess) provision for Current tax related to earlier years |
-31.09 |
0.69 |
|
Deferref Tax |
36.07 |
-114.84 |
|
Current Tax relating to Revenue account |
65.64 |
68.50 |
|
Profit for the Year |
3,438.89 |
4,824.07 |
|
Other Comprehensive Income |
56.73 |
-102.29 |
|
Relating to Revenue Account of Life Insurance Policyholders |
|
|
|
Items that will not be reclassified to profit or loss in subsequent
periods |
-10.04 |
-2.70 |
|
Items that will be reclassified to profit or loss in subsequent
periods |
523.18 |
-126.48 |
|
Less: Transferred to Policyholders ' Fund in the Balance Sheet |
-513.18 |
129.18 |
|
Relating to Revenue Account of Health Insurance Policyholders |
|
|
|
Items that will not be reclassified to profit or loss in subsequent
periods |
- |
0.36 |
|
Items that will be reclassified to profit or loss in subsequent
periods |
- |
-35.96 |
|
Related to Others |
|
|
|
Items that will not be reclassified to profit or loss in subsequent
periods |
56.41 |
0.06 |
|
Income Tax relating to items that will not be reclassified to profit
or loss |
-20.88 |
-0.72 |
|
Items that will be reclassified to profit or loss in subsequent
periods |
21.79 |
-76.29 |
|
Income Tax relating to items that will be reclassified to profit or
loss |
-0.59 |
10.26 |
|
Other Comprehensive Income for the Year |
56.73 |
-102.29 |
|
Total Comprehensive Income |
3,495.62 |
4,721.78 |
|
Profit for the Year attributable to |
|
|
|
Owners of the Company |
3,334.98 |
4,795.77 |
|
Non-Controlling Interests |
103.91 |
28.30 |
|
Other Comprehensive Income for the Year attributable to |
|
|
|
Owners of the Company |
20.94 |
-40.44 |
|
Non-Controlling Interests |
35.79 |
-61.85 |
|
Total Comprehensive Income |
|
|
|
Owners of the Company |
3,355.92 |
4,755.33 |
|
Non-Controlling Interests |
139.70 |
-33.55 |
|
Earnings Per Share - Basic |
13.05 |
19.84 |
|
Earnings Per Share - Diluted |
12.95 |
19.77 |
|
Particulars |
31-03-2024 |
31-03-2023 |
|
Cash Flow from Operating Activities |
|
|
|
Profit Before Share of Associates and Joint Ventures and Tax |
4,278.45 |
5,362.66 |
|
Adjustment For: |
|
|
|
Expense on Employee Stock Options Scheme |
102.65 |
44.64 |
|
Impairment on Financial Instruments |
1,353.20 |
983.46 |
|
Net Gain on Fair Value Changes |
-792.96 |
-154.44 |
|
Gain on Sale of Investment |
-486.43 |
0.00 |
|
Change in Valuation of Insurance Liabilities |
7,861.66 |
7,451.57 |
|
Fair Value Gain on Conversion to JV |
- |
-2,739.07 |
|
Depreciation and Amortisation |
291.44 |
252.38 |
|
Profit/(Loss) on Sale of Property, Plant and Equipment |
0.36 |
0.58 |
|
Operating Profit Before Working Capital Changes |
12,608.37 |
11,201.78 |
|
Adjustment For: |
|
|
|
Change in Trade Receivables |
-306.45 |
245.55 |
|
Change in Loans |
-31,066.25 |
-28,190.15 |
|
Change in Other Assets |
-153.60 |
-191.52 |
|
Change in Trade Payables |
6.51 |
712.48 |
|
Change in Provisions |
63.27 |
-36.53 |
|
Change in Policyholders ' Net Assets |
-7,229.70 |
-7,523.41 |
|
Change in Other Liabilities |
2,864.59 |
313.76 |
|
Cash Generated from Operations |
-23,213.26 |
-23,468.04 |
|
Income Taxes Paid |
-887.24 |
-560.55 |
|
Net Cash from Operating Activities |
-24,100.50 |
-24,028.59 |
|
Cash Flow from Investing Activities |
|
|
|
Additions to Fixed and Intangible Assets |
-402.41 |
-245.58 |
|
Proceeds from Sale of Fixed Assets |
4.24 |
5.83 |
|
Purchase of Long-Term Investments |
-114.10 |
-416.10 |
|
Proceeds from Sale of Long-Term Investments |
369.03 |
231.97 |
|
Sale of Investment in Associate Company |
639.00 |
0.00 |
|
Net Purchase of Insurance Shareholders’ Investments |
-628.30 |
-447.90 |
|
Net Purchase/Sale of Current Investments |
-3,137.11 |
-1,937.51 |
|
Movement in Long-Term Deposits |
-1,396.26 |
3.15 |
|
Dividend Received |
75.62 |
156.27 |
|
Net Cash from Investing Activities |
-4,590.29 |
-2,649.87 |
|
Cash Flow from Financing Activities |
|
|
|
ESOP Proceeds |
70.47 |
8.91 |
|
Proceeds from Share Issue (Net) |
2,962.63 |
0.00 |
|
Subsidiary Share Issue to NCI |
171.50 |
267.05 |
|
Proceeds from Long-Term Borrowings |
32,860.11 |
35,390.80 |
|
Repayment of Long-Term Borrowings |
-16,578.01 |
-14,505.91 |
|
Net Short-Term Borrowings |
9,131.02 |
5,351.54 |
|
Lease Liability Payments |
-107.82 |
-98.23 |
|
Dividend Paid to NCI |
0.00 |
-30.01 |
|
Share Application Money Received |
4.40 |
1.06 |
|
Net Cash from Financing Activities |
28,514.30 |
26,385.21 |
|
Net Decrease in Cash and Cash Equivalents |
-176.49 |
-293.25 |
|
Opening Cash and Cash Equivalents |
1,730.79 |
2,048.85 |
|
Adjustment from Conversion to JV |
0.00 |
-24.81 |
|
Closing Cash and Cash Equivalents |
1,554.30 |
1,730.79 |
Cash Flow from
Operating Activities
In FY 2023–24, the
company started with a profit before share of associates,
joint ventures, and tax of ₹4,278.45 crore (down from ₹5,362.66
crore in FY 2022–23).
Several non-cash
adjustments were made, including:
Employee
stock options expense increased significantly to ₹102.65 crore.
Impairment
on financial instruments also rose to ₹1,353.20 crore, showing
greater provisioning.
Net
gain on fair value changes and gain on sale of
investments were deducted (as they are non-operating), reducing
cash by ₹792.96 crore and ₹486.43 crore, respectively.
Change
in insurance liabilities valuation added ₹7,861.66
crore, reflecting policy-related obligations.
In the previous year,
a one-time gain
of ₹2,739.07 crore was recognized due to the conversion of
Aditya Birla Health Insurance into a joint venture.
After including depreciation,
amortisation, and minor gains/losses on asset sales,
the operating
profit before working capital changes was ₹12,608.37 crore.
However, significant
cash outflows were observed due to:
A sharp
increase in loans disbursed (-₹31,066.25 crore),
A reduction
in net policyholder assets (-₹7,229.70 crore), and
Increases in other
liabilities provided partial relief.
Ultimately, after
paying taxes of ₹887.24 crore, the net cash used in operating activities
stood at -₹24,100.50
crore, similar to last year 's outflow of -₹24,028.59 crore.
This suggests heavy reinvestment and expansion in lending and insurance operations.
Cash Flow from Investing Activities
Net cash used in
investing increased to -₹4,590.29 crore in
FY24 from -₹2,649.87
crore in FY23.
Key contributors:
Investments
in current and long-term instruments (₹3,137.11 crore
and ₹114.10 crore respectively).
Purchase
of insurance-related investments (₹628.30 crore).
Proceeds
from sale of investments, including a significant ₹639.00 crore from
selling an associate company.
Additions
to fixed and intangible assets rose to ₹402.41
crore.
Though dividend
income and sale proceeds supported inflows, the company 's investing activities
remain in outflow mode due to asset acquisitions and capital allocation in
financial instruments.
Cash Flow from Financing Activities
This section saw strong
positive cash flow of ₹28,514.30 crore in FY24 (up from
₹26,385.21 crore in FY23), mainly due to:
Fresh
long-term borrowings of ₹32,860.11 crore,
Equity
infusion through share issues amounting to ₹2,962.63 crore,
Subsidiary
capital raising of ₹171.50 crore,
Net short-term
borrowing of ₹9,131.02 crore.
Repayments and
payments like lease liabilities and dividends were minimal in comparison,
allowing the financing segment to more than offset operating and investing cash
outflows.
Net Movement in Cash and Cash Equivalents
The overall net
decrease in cash stood at -₹176.49 crore
(improved from -₹293.25 crore in FY23).
Starting from an
opening balance of ₹1,730.79 crore, and with no JV-related adjustments this
year, the company ended FY24 with ₹1,554.30 crore in cash and cash
equivalents.